skip to main content

United Therapeutics Corporation To Present At 33rd Annual J.P. Morgan Healthcare Conference

SILVER SPRING, Md., Jan. 6, 2015 /PRNewswire/ -- United Therapeutics Corporation (NASDAQ: UTHR) announced today that Martine Rothblatt, Ph.D., Chairman and Co-Chief Executive Officer, and Roger Jeffs, Ph.D., President and Co-Chief Executive Officer, of United Therapeutics will provide an overview and update on the company's business at the 33rd Annual J.P. Morgan Healthcare Conference in San Francisco, California.

The presentation and the immediately following Q&A breakout session will take place on Monday, January 12, 2015, at 4:00 PM Pacific Standard Time, and can be accessed via a live webcast on the United Therapeutics website at http://www.unither.com under the "Investor" tab in the "Events and Presentations" section. An archived, recorded version of the presentation and the Q&A breakout session will be available approximately twenty-four hours after the Q&A breakout session ends and can be accessed at the same location for 90 days. [uthr-g]

About United Therapeutics

United Therapeutics Corporation is a biotechnology company focused on the development and commercialization of unique products to address the unmet medical needs of patients with chronic and life-threatening conditions. 

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/united-therapeutics-corporation-to-present-at-33rd-annual-jp-morgan-healthcare-conference-300016991.html

SOURCE United Therapeutics Corporation

Recent Press Releases

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)-- United Therapeutics Corporation (Nasdaq: UTHR) announced today that James Edgemond, Chief Financial Officer and Treasurer, will provide an...
The transaction eliminates the double-digit royalty payable to Pfizer on net sales of ralinepag Royalty elimination applies to all formulations of ralinepag, including both oral and inhaled SILVER SPRING, Md...
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)-- United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced its financial results for the quarter ended...
If successful, Treprostinil-Iloprost SMI would be the first use-as-needed combination inhaled therapy to be developed for pulmonary arterial hypertension (PAH) This investigational therapy combines two potent...
SILVER SPRING, M.D. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)-- United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced today that the company’s Board of Directors has...
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)-- United Therapeutics Corporation (Nasdaq: UTHR) announced today that it will report its third quarter 2026 financial results in a press release...